Delaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Clinical Medicine Insights. Oncology
Adam M Brufsky

Abstract

Global guidelines for the management of locally advanced or metastatic hormone receptor-positive (HR-positive), human epidermal growth factor 2-negative (HER2-negative) breast cancer recommend endocrine therapy as first-line treatment for all patients, regardless of age or postmenopausal status. However, current practice patterns in the United States and Europe suggest that these modes of therapy are not being used as recommended, and many patients with advanced HR-positive, HER2-negative disease are being treated first-line with chemotherapy or switched to chemotherapy after a single endocrine therapy. Given that chemotherapy is associated with increased toxicity and reduced quality of life (QOL) compared with endocrine therapy, prolonging the duration of response obtained with endocrine therapy may help delay chemotherapy and its attendant toxicities. Several strategies to delay or overcome endocrine resistance and thereby postpone chemotherapy have been explored, including the use of second-line endocrine agents with different mechanisms of action, adding targeted agents that inhibit specific resistance pathways, and adding agents that act in complementary or synergistic ways to inhibit tumor cell proliferation. This review ...Continue Reading

References

Aug 23, 2000·European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)·B KuschelM W Beckmann
Nov 1, 2002·Breast Cancer Research and Treatment·William F AndersonOtis W Brawley
Mar 19, 2003·European Journal of Cancer Care·Barbara LiebertUNKNOWN National Breast Cancer Centre's Specialist Breast Nurse Project Team
Dec 22, 2005·The Oncologist·Joyce O'Shaughnessy
Sep 21, 2006·Journal of the National Cancer Institute·Davide MauriJohn P A Ioannidis
Mar 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Massimo CristofanilliPatrick J Magill
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CardosoUNKNOWN ESMO Guidelines Working Group
Sep 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Angelo Di LeoMiguel Martin
Sep 13, 2011·World Journal of Clinical Oncology·Jennifer D Davis, Shiaw-Yih Lin
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Dec 23, 2011·Molecular Cancer Therapeutics·Sauveur-Michel MairaCharles F Voliva
Aug 7, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M S N Mohd SharialB T Hennessy
Nov 20, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CardosoUNKNOWN ESMO Guidelines Working Group
Oct 12, 2012·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Izo Kimijima
Dec 12, 2012·Clinical Breast Cancer·Rowan T Chlebowski
Feb 22, 2013·Journal of the National Cancer Institute·Michael GnantKathleen I Pritchard
Mar 6, 2013·Nature Reviews. Clinical Oncology·Dimitrios ZardavasMartine Piccart
Jun 6, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Mario CamponeMartine Piccart
Sep 10, 2013·Surgical Oncology Clinics of North America·Karen A CadooTari A King
Nov 8, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard S FinnStephen Johnston
Dec 10, 2013·Journal of the National Cancer Institute·Angelo Di LeoMiguel Martin
Dec 24, 2013·Breast Cancer Research and Treatment·J Thaddeus BeckMartine Piccart
Jan 3, 2014·The Journal of Clinical Investigation·Alison C West, Ricky W Johnstone
Feb 27, 2014·Journal of Hypertension·Peter WohlfahrtRenata Cifkova
Mar 26, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ingrid A MayerCarlos L Arteaga

❮ Previous
Next ❯

Citations

Apr 5, 2016·Expert Opinion on Pharmacotherapy·Roberto Filippi, Filippo Montemurro
Jan 11, 2017·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Satoshi TanakaMinoru Sakaguchi
Feb 14, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·I Alvarez-LopezA Santaballa Bertrán

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01602380
NCT01740427
NCT01942135
NCT02115282
NCT02203513

Software Mentioned

MONALEESA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.